Xtl Biopharmaceuticals XTLB
NASDAQ XTLB
$2.21 -0.02 (-0.91%)
As of: Sep 29, 2026 · 3:40 PM EDT

Xtl Biopharmaceuticals (XTLB) Current Debt (2009 - 2012)

Updated

Xtl Biopharmaceuticals (XTLB) recorded Current Debt of -$170,000 in the year ended Dec 31, 2012, compared with -$1.38 million a year earlier.

Analysis

Xtl Biopharmaceuticals (XTLB) Current Debt (2009 - 2012) Analysis & Trends

  • Per Business Quant data, XTLB's Current Debt was -$1.38 million in the year ended Dec 31, 2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Debt (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn -
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn -
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 208.00 Mn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 37.00 Mn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn -
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 64.00 Mn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Xtl Biopharmaceuticals 2.11 Bn 2.11 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2012 -2.00 Mn
Jun 30, 2011 25,000.00
Mar 31, 2011 -1.87 Mn
Sep 30, 2009 31,000.00
API Access

Xtl Biopharmaceuticals Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-debt&ticker=XTLB&period=max&api_key=YOUR_API_KEY